TY - JOUR
T1 - Daily melatonin administration to middle-aged male rats suppresses body weight, intraabdominal adiposity, and plasma leptin and insulin independent of food intake and total body fat
AU - Wolden-Hanson, T.
AU - Mitton, D. R.
AU - McCants, R. L.
AU - Yellon, S. M.
AU - Wilkinson, C. W.
AU - Matsumoto, A. M.
AU - Rasmussen, D. D.
N1 - THE PINEAL GLAND secretes melatonin into the circulation almost entirely at night in vertebrates ( 1, 2). This nocturnal secretion mediates entrainment of endogenous circadian rhythms and influences other physiological functions. Pineal melatonin biosynthesis and secretion decline with aging; levels are significantly decreased by middle age ( 2, 3) and tend to decline throughout old age.
PY - 2000/2
Y1 - 2000/2
N2 - Pineal melatonin secretion declines with aging, whereas visceral fat, plasma insulin, and plasma leptin tend to increase. We have previously demonstrated that daily melatonin administration at middle age suppressed male rat intraabdominal visceral fat, plasma leptin, and plasma insulin to youthful levels; the current study was designed to begin investigating mechanisms that mediate these responses. Melatonin (0.4 μg/ml) or vehicle was administered in the drinking water of 10-month-old male Sprague Dawley rats (18/treatment) for 12 weeks. Half(9/treatment) were then killed, and the other half were submitted to cross-over treatment for an additional 12 weeks. Twelve weeks of melatonin treatment decreased (P < 0.05) body weight (BW; by 7% relative to controls), relative intraabdominal adiposity (by 16%), plasma leptin (by 33%), and plasma insulin (by 25%) while increasing (P < 0.05) locomotor activity (by 19%), core body temperature (by 0.5 C), and morning plasma corticosterone (by 154%), restoring each of these parameters toward more youthful levels. Food intake and total body fat were not changed by melatonin treatment. Melatonin-treated rats that were then crossed over to control treatment for a further 12 weeks gained BW, whereas control rats that were crossed to melatonin treatment lost BW, but food intake did not change in either group. Feed efficiency (grams of BW change per g cumulative food intake), a measure of metabolic function, was negative in melatonin-treated rats and positive in control rats before cross-over (P < 0.001); this relationship was reversed after cross-over (P < 0.001). Thus, melatonin treatment in middle age decreased BW, intraabdominal adiposity, plasma insulin, and plasma leptin, without altering food intake or total adiposity. These results suggest that the decrease in endogenous melatonin with aging may alter metabolism and physical activity, resulting in increased BW, visceral adiposity, and associated detrimental metabolic consequences.
AB - Pineal melatonin secretion declines with aging, whereas visceral fat, plasma insulin, and plasma leptin tend to increase. We have previously demonstrated that daily melatonin administration at middle age suppressed male rat intraabdominal visceral fat, plasma leptin, and plasma insulin to youthful levels; the current study was designed to begin investigating mechanisms that mediate these responses. Melatonin (0.4 μg/ml) or vehicle was administered in the drinking water of 10-month-old male Sprague Dawley rats (18/treatment) for 12 weeks. Half(9/treatment) were then killed, and the other half were submitted to cross-over treatment for an additional 12 weeks. Twelve weeks of melatonin treatment decreased (P < 0.05) body weight (BW; by 7% relative to controls), relative intraabdominal adiposity (by 16%), plasma leptin (by 33%), and plasma insulin (by 25%) while increasing (P < 0.05) locomotor activity (by 19%), core body temperature (by 0.5 C), and morning plasma corticosterone (by 154%), restoring each of these parameters toward more youthful levels. Food intake and total body fat were not changed by melatonin treatment. Melatonin-treated rats that were then crossed over to control treatment for a further 12 weeks gained BW, whereas control rats that were crossed to melatonin treatment lost BW, but food intake did not change in either group. Feed efficiency (grams of BW change per g cumulative food intake), a measure of metabolic function, was negative in melatonin-treated rats and positive in control rats before cross-over (P < 0.001); this relationship was reversed after cross-over (P < 0.001). Thus, melatonin treatment in middle age decreased BW, intraabdominal adiposity, plasma insulin, and plasma leptin, without altering food intake or total adiposity. These results suggest that the decrease in endogenous melatonin with aging may alter metabolism and physical activity, resulting in increased BW, visceral adiposity, and associated detrimental metabolic consequences.
KW - Abdomen
KW - Absorptiometry, Photon
KW - Adipose Tissue/anatomy & histology
KW - Administration, Oral
KW - Adrenal Glands/drug effects
KW - Animals
KW - Avoidance Learning/drug effects
KW - Body Temperature/drug effects
KW - Body Weight/drug effects
KW - Choice Behavior
KW - Drinking Behavior/drug effects
KW - Drug Administration Schedule
KW - Energy Intake/drug effects
KW - Insulin/blood
KW - Leptin/blood
KW - Male
KW - Melatonin/administration & dosage
KW - Motor Activity/drug effects
KW - Organ Size/drug effects
KW - Rats
KW - Rats, Sprague-Dawley
KW - Saccharin
KW - Taste
KW - Thymus Gland/drug effects
UR - https://www.scopus.com/pages/publications/0034465880
UR - https://www.scopus.com/pages/publications/0034465880#tab=citedBy
UR - https://www.mendeley.com/catalogue/03cb8269-8934-32ca-a5c9-c31cb1f6ebc4/
U2 - 10.1210/endo.141.2.7311
DO - 10.1210/endo.141.2.7311
M3 - Article
C2 - 10650927
SN - 0013-7227
VL - 141
SP - 487
EP - 497
JO - Endocrinology
JF - Endocrinology
IS - 2
ER -